Antiproliferative activity of novel imidazopyridine derivatives on castration-resistant human prostate cancer cells

Sakthivel Muniyan, Yu Wei Chou, Matthew A. Ingersoll, Alexus Devine, Marisha Morris, Valerie A. Odero-Marah, Shafiq A. Khan, William G Chaney, Xiu R. Bu, Ming-Fong Lin

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Metastatic prostate cancer (mPCa) relapses after a short period of androgen deprivation therapy and becomes the castration-resistant prostate cancer (CR PCa); to which the treatment is limited. Hence, it is imperative to identify novel therapeutic agents towards this patient population. In the present study, antiproliferative activities of novel imidazopyridines were compared. Among three derivatives, PHE, AMD and AMN, examined, AMD showed the highest inhibitory activity on LNCaP C-81 cell proliferation, following dose- and time-dependent manner. Additionally, AMD exhibited significant antiproliferative effect against a panel of PCa cells, but not normal prostate epithelial cells. Further, when compared to AMD, its derivative DME showed higher inhibitory activities on PCa cell proliferation, clonogenic potential and in vitro tumorigenicity. The inhibitory activity was apparently in part due to the induction of apoptosis. Mechanistic studies indicate that AMD and DME treatments inhibited both AR and PI3K/Akt signaling. The results suggest that better understanding of inhibitory mechanisms of AMD and DME could help design novel therapeutic agents for improving the treatment of CR PCa.

Original languageEnglish (US)
Pages (from-to)59-67
Number of pages9
JournalCancer Letters
Volume353
Issue number1
DOIs
StatePublished - Jan 1 2014

Fingerprint

Castration
Prostatic Neoplasms
Therapeutics
Cell Proliferation
Proxy
Phosphatidylinositol 3-Kinases
Androgens
Prostate
Epithelial Cells
Apoptosis
Recurrence
Population

Keywords

  • Androgen receptor
  • Imidazopyridine
  • P66Shc
  • PI3K/Akt
  • Prostate cancer

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Antiproliferative activity of novel imidazopyridine derivatives on castration-resistant human prostate cancer cells. / Muniyan, Sakthivel; Chou, Yu Wei; Ingersoll, Matthew A.; Devine, Alexus; Morris, Marisha; Odero-Marah, Valerie A.; Khan, Shafiq A.; Chaney, William G; Bu, Xiu R.; Lin, Ming-Fong.

In: Cancer Letters, Vol. 353, No. 1, 01.01.2014, p. 59-67.

Research output: Contribution to journalArticle

Muniyan, S, Chou, YW, Ingersoll, MA, Devine, A, Morris, M, Odero-Marah, VA, Khan, SA, Chaney, WG, Bu, XR & Lin, M-F 2014, 'Antiproliferative activity of novel imidazopyridine derivatives on castration-resistant human prostate cancer cells', Cancer Letters, vol. 353, no. 1, pp. 59-67. https://doi.org/10.1016/j.canlet.2014.07.002
Muniyan, Sakthivel ; Chou, Yu Wei ; Ingersoll, Matthew A. ; Devine, Alexus ; Morris, Marisha ; Odero-Marah, Valerie A. ; Khan, Shafiq A. ; Chaney, William G ; Bu, Xiu R. ; Lin, Ming-Fong. / Antiproliferative activity of novel imidazopyridine derivatives on castration-resistant human prostate cancer cells. In: Cancer Letters. 2014 ; Vol. 353, No. 1. pp. 59-67.
@article{8c148f3440fe4437aecdc0c91c9d2532,
title = "Antiproliferative activity of novel imidazopyridine derivatives on castration-resistant human prostate cancer cells",
abstract = "Metastatic prostate cancer (mPCa) relapses after a short period of androgen deprivation therapy and becomes the castration-resistant prostate cancer (CR PCa); to which the treatment is limited. Hence, it is imperative to identify novel therapeutic agents towards this patient population. In the present study, antiproliferative activities of novel imidazopyridines were compared. Among three derivatives, PHE, AMD and AMN, examined, AMD showed the highest inhibitory activity on LNCaP C-81 cell proliferation, following dose- and time-dependent manner. Additionally, AMD exhibited significant antiproliferative effect against a panel of PCa cells, but not normal prostate epithelial cells. Further, when compared to AMD, its derivative DME showed higher inhibitory activities on PCa cell proliferation, clonogenic potential and in vitro tumorigenicity. The inhibitory activity was apparently in part due to the induction of apoptosis. Mechanistic studies indicate that AMD and DME treatments inhibited both AR and PI3K/Akt signaling. The results suggest that better understanding of inhibitory mechanisms of AMD and DME could help design novel therapeutic agents for improving the treatment of CR PCa.",
keywords = "Androgen receptor, Imidazopyridine, P66Shc, PI3K/Akt, Prostate cancer",
author = "Sakthivel Muniyan and Chou, {Yu Wei} and Ingersoll, {Matthew A.} and Alexus Devine and Marisha Morris and Odero-Marah, {Valerie A.} and Khan, {Shafiq A.} and Chaney, {William G} and Bu, {Xiu R.} and Ming-Fong Lin",
year = "2014",
month = "1",
day = "1",
doi = "10.1016/j.canlet.2014.07.002",
language = "English (US)",
volume = "353",
pages = "59--67",
journal = "Cancer Letters",
issn = "0304-3835",
publisher = "Elsevier Ireland Ltd",
number = "1",

}

TY - JOUR

T1 - Antiproliferative activity of novel imidazopyridine derivatives on castration-resistant human prostate cancer cells

AU - Muniyan, Sakthivel

AU - Chou, Yu Wei

AU - Ingersoll, Matthew A.

AU - Devine, Alexus

AU - Morris, Marisha

AU - Odero-Marah, Valerie A.

AU - Khan, Shafiq A.

AU - Chaney, William G

AU - Bu, Xiu R.

AU - Lin, Ming-Fong

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Metastatic prostate cancer (mPCa) relapses after a short period of androgen deprivation therapy and becomes the castration-resistant prostate cancer (CR PCa); to which the treatment is limited. Hence, it is imperative to identify novel therapeutic agents towards this patient population. In the present study, antiproliferative activities of novel imidazopyridines were compared. Among three derivatives, PHE, AMD and AMN, examined, AMD showed the highest inhibitory activity on LNCaP C-81 cell proliferation, following dose- and time-dependent manner. Additionally, AMD exhibited significant antiproliferative effect against a panel of PCa cells, but not normal prostate epithelial cells. Further, when compared to AMD, its derivative DME showed higher inhibitory activities on PCa cell proliferation, clonogenic potential and in vitro tumorigenicity. The inhibitory activity was apparently in part due to the induction of apoptosis. Mechanistic studies indicate that AMD and DME treatments inhibited both AR and PI3K/Akt signaling. The results suggest that better understanding of inhibitory mechanisms of AMD and DME could help design novel therapeutic agents for improving the treatment of CR PCa.

AB - Metastatic prostate cancer (mPCa) relapses after a short period of androgen deprivation therapy and becomes the castration-resistant prostate cancer (CR PCa); to which the treatment is limited. Hence, it is imperative to identify novel therapeutic agents towards this patient population. In the present study, antiproliferative activities of novel imidazopyridines were compared. Among three derivatives, PHE, AMD and AMN, examined, AMD showed the highest inhibitory activity on LNCaP C-81 cell proliferation, following dose- and time-dependent manner. Additionally, AMD exhibited significant antiproliferative effect against a panel of PCa cells, but not normal prostate epithelial cells. Further, when compared to AMD, its derivative DME showed higher inhibitory activities on PCa cell proliferation, clonogenic potential and in vitro tumorigenicity. The inhibitory activity was apparently in part due to the induction of apoptosis. Mechanistic studies indicate that AMD and DME treatments inhibited both AR and PI3K/Akt signaling. The results suggest that better understanding of inhibitory mechanisms of AMD and DME could help design novel therapeutic agents for improving the treatment of CR PCa.

KW - Androgen receptor

KW - Imidazopyridine

KW - P66Shc

KW - PI3K/Akt

KW - Prostate cancer

UR - http://www.scopus.com/inward/record.url?scp=84908363931&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84908363931&partnerID=8YFLogxK

U2 - 10.1016/j.canlet.2014.07.002

DO - 10.1016/j.canlet.2014.07.002

M3 - Article

VL - 353

SP - 59

EP - 67

JO - Cancer Letters

JF - Cancer Letters

SN - 0304-3835

IS - 1

ER -